How to buy Ironwood Pharmaceuticals stock

Ironwood Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around USD0.00.

Ironwood Pharmaceuticals share price

Use our graph to track the performance of IRWD stocks over time.

Ironwood Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-16.

52-week range	USD$8.63 - USD$12.55
50-day moving average	USD$10.5691
200-day moving average	USD$10.71
Wall St. target price	USD$12.29
PE ratio	16.4242
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.66

Buy Ironwood Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Ironwood Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Ironwood Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Ironwood Pharmaceuticals under- or over-valued?

Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ironwood Pharmaceuticals's P/E ratio

Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Ironwood Pharmaceuticals shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Ironwood Pharmaceuticals's EBITDA

Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$161.3 million.

The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Ironwood Pharmaceuticals financials

Revenue TTM	USD$389.5 million
Operating margin TTM	40.8%
Gross profit TTM	USD$298.3 million
Return on assets TTM	20.65%
Return on equity TTM	0%
Profit margin	27.26%
Book value	$0.39
Market capitalisation	USD$1.7 billion

TTM: trailing 12 months

Shorting Ironwood Pharmaceuticals shares

There are currently 19.5 million Ironwood Pharmaceuticals shares held short by investors – that's known as Ironwood Pharmaceuticals's "short interest". This figure is 5% down from 20.5 million last month.

There are a few different ways that this level of interest in shorting Ironwood Pharmaceuticals shares can be evaluated.

Ironwood Pharmaceuticals's "short interest ratio" (SIR)

Ironwood Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ironwood Pharmaceuticals shares currently shorted divided by the average quantity of Ironwood Pharmaceuticals shares traded daily (recently around 2.9 million). Ironwood Pharmaceuticals's SIR currently stands at 6.82. In other words for every 100,000 Ironwood Pharmaceuticals shares traded daily on the market, roughly 6820 shares are currently held short.

However Ironwood Pharmaceuticals's short interest can also be evaluated against the total number of Ironwood Pharmaceuticals shares, or, against the total number of tradable Ironwood Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ironwood Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Ironwood Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1886% of the tradable shares (for every 100,000 tradable Ironwood Pharmaceuticals shares, roughly 189 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ironwood Pharmaceuticals.

Find out more about how you can short Ironwood Pharmaceuticals stock.

Ironwood Pharmaceuticals share dividends

We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.

Have Ironwood Pharmaceuticals's shares ever split?

Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 1 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.

Ironwood Pharmaceuticals share price volatility

Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $8.63 up to $12.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 1.3651. This would suggest that Ironwood Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ironwood Pharmaceuticals overview

Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc. , AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.

Frequently asked questions

• What percentage of Ironwood Pharmaceuticals is owned by insiders or institutions?

  Currently 3.085% of Ironwood Pharmaceuticals shares are held by insiders and 109.903% by institutions.

• How many people work for Ironwood Pharmaceuticals?

  Latest data suggests 232 work at Ironwood Pharmaceuticals.

• When does the fiscal year end for Ironwood Pharmaceuticals?

  Ironwood Pharmaceuticals's fiscal year ends in December.

• Where is Ironwood Pharmaceuticals based?

  Ironwood Pharmaceuticals's address is: 100 Summer Street, Boston, MA, United States, 02110

• What is Ironwood Pharmaceuticals's ISIN number?

  Ironwood Pharmaceuticals's international securities identification number is: US46333X1081

• What is Ironwood Pharmaceuticals's CUSIP number?

  Ironwood Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 46333X108